NAYA Biosciences Corp - Wutah pendapatan taun lumaku NAYA

Combating oncology via the Flex-NK platform requires the integration of reproductive medicine, as illustrated by the 12-month year-over-year revenue change history, where the 0.00 mark serves as a key metric for NAYA Biosciences (NAYA). Development relies on intensive validation of bispecific antibodies and tight testing cycles, while the operating model is based on the full outsourcing of research to external CRO vendors.
NAYA Biosciences Inc (NAYA) - rincian metrik lan laporan keuangan

This indicator measures the percentage change in aggregate revenue over the last twelve months relative to the same period last year, allowing analysts to distinguish random spikes from a sustainable trend. By analyzing the current year-over-year (TTM) sales momentum, an investor can assess the commercial efficiency of NAYA Biosciences' innovative oncology developments, which determines the asset's fundamental value during clinical trial stages.